Merck (MRK) Cash & Equivalents (2009 - 2026)
Merck (MRK) reported Cash & Equivalents of $5.3 billion for Q1 2026, down 38.27% year-over-year from $8.6 billion in Q1 2025, and down 63.43% on a QoQ basis from $14.6 billion in Q4 2025.
Merck (MRK) has 18 years of Cash & Equivalents data on file, last reported at $5.3 billion in Q1 2026.
- Quarterly Cash & Equivalents fell 38.27% year-over-year to $5.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 billion (down 38.27% YoY) and the FY2025 annual result came in at $14.6 billion, up 9.99% from the prior year.
- Cash & Equivalents declined to $5.3 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $18.2 billion in Q3 2025 and bottomed at $5.3 billion in Q1 2026.
- The 5-year median for Cash & Equivalents is $9.7 billion (2022), against an average of $10.1 billion.
- The widest annual swing landed in 2023, when Cash & Equivalents slumped 46.11%; it then jumped 99.72% in 2024.
- Tracing MRK's Cash & Equivalents over 5 years: stood at $12.7 billion in 2022, then tumbled by 46.11% to $6.8 billion in 2023, then soared by 93.57% to $13.2 billion in 2024, then advanced by 9.99% to $14.6 billion in 2025, then tumbled by 63.43% to $5.3 billion in 2026.
- Per Business Quant, the three latest MRK Cash & Equivalents figures stand at $5.3 billion (Q1 2026), $14.6 billion (Q4 2025), and $18.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 4.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.33 Bn |
| Dec 31, 2025 | 14.57 Bn |
| Sep 30, 2025 | 18.17 Bn |
| Jun 30, 2025 | 8.01 Bn |
| Mar 31, 2025 | 8.63 Bn |
| Dec 31, 2024 | 13.24 Bn |
| Sep 30, 2024 | 14.59 Bn |
| Jun 30, 2024 | 11.30 Bn |
| Mar 31, 2024 | 5.58 Bn |
| Dec 31, 2023 | 6.84 Bn |
| Sep 30, 2023 | 8.61 Bn |
| Jun 30, 2023 | 5.66 Bn |
| Mar 31, 2023 | 9.71 Bn |
| Dec 31, 2022 | 12.69 Bn |
| Sep 30, 2022 | 11.15 Bn |
| Jun 30, 2022 | 9.68 Bn |
| Mar 31, 2022 | 8.56 Bn |
| Dec 31, 2021 | 8.10 Bn |
| Sep 30, 2021 | 10.02 Bn |
| Jun 30, 2021 | 8.58 Bn |
| Mar 31, 2021 | 6.98 Bn |
| Dec 31, 2020 | 8.05 Bn |
| Sep 30, 2020 | 7.36 Bn |
| Jun 30, 2020 | 11.10 Bn |
| Mar 31, 2020 | 7.43 Bn |
| Dec 31, 2019 | 9.68 Bn |
| Sep 30, 2019 | 7.87 Bn |
| Jun 30, 2019 | 6.66 Bn |
| Mar 31, 2019 | 8.08 Bn |
| Dec 31, 2018 | 7.97 Bn |
| Sep 30, 2018 | 7.83 Bn |
| Jun 30, 2018 | 5.31 Bn |
| Mar 31, 2018 | 4.48 Bn |
| Dec 31, 2017 | 6.09 Bn |
| Sep 30, 2017 | 7.90 Bn |
| Jun 30, 2017 | 7.79 Bn |
| Mar 31, 2017 | 11.71 Bn |
| Dec 31, 2016 | 6.52 Bn |
| Sep 30, 2016 | 7.91 Bn |
| Jun 30, 2016 | 6.61 Bn |
| Mar 31, 2016 | 9.72 Bn |
| Dec 31, 2015 | 8.52 Bn |
| Sep 30, 2015 | 7.55 Bn |
| Jun 30, 2015 | 6.92 Bn |
| Mar 31, 2015 | 7.98 Bn |
| Dec 31, 2014 | 7.44 Bn |
| Sep 30, 2014 | 11.37 Bn |
| Jun 30, 2014 | 9.74 Bn |
| Mar 31, 2014 | 15.83 Bn |
| Dec 31, 2013 | 15.62 Bn |
| Sep 30, 2013 | 14.09 Bn |
| Jun 30, 2013 | 15.09 Bn |
| Mar 31, 2013 | 13.02 Bn |
| Dec 31, 2012 | 13.45 Bn |
| Sep 30, 2012 | 17.36 Bn |
| Jun 30, 2012 | 16.75 Bn |
| Mar 31, 2012 | 14.66 Bn |
| Dec 31, 2011 | 13.53 Bn |
| Sep 30, 2011 | 13.30 Bn |
| Jun 30, 2011 | 12.34 Bn |
| Mar 31, 2011 | 11.70 Bn |
| Dec 31, 2010 | 10.90 Bn |
| Sep 30, 2010 | 9.87 Bn |
| Jun 30, 2010 | 8.67 Bn |
| Mar 31, 2010 | 8.24 Bn |
| Dec 31, 2009 | 9.31 Bn |
| Sep 30, 2009 | 21.82 Bn |
| Jun 30, 2009 | 12.46 Bn |
| Mar 31, 2009 | 6.02 Bn |